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Abstract
Background: Papillary thyroid microcarcinoma (PTMC) is defined as a papillary thyroid carcinoma
less than or equal to 1.0 cm in size. Independent prognostic factors for clinical recurrence of PTMC
have not been clearly delineated.
Methods:  Clinicopathological parameters predicting PTMC recurrence were determined by
retrospective analysis of 307 patients.
Results: Of the 293 patients eligible for analysis, 14 (5%) had recurrence during a median follow-
up time of 65 months. Recurrence was observed in 8 of 166 patients (0.5%) treated with total or
near-total thyroidectomy; gender (P = 0.02) and presence of lateral cervical node metastases at
initial surgery (P = 0.01) were associated with recurrence. Six of the 127 patients (0.5%) treated
with hemi- or subtotal thyroidectomy experience recurrences, but no significant prognostic factor
for recurrence was identified. Multivariate Cox-regression analysis showed that gender and cervical
lymph node metastasis were significant variables
Conclusion: PTMC showed very diverse disease extent and could not be regarded as indolent,
relatively benign disease based on the primary tumor size. The extent of surgery should be based
on prognostic parameters, such as gender and lateral neck node metastasis, in patients with PTMC.
Background
Papillary thyroid microcarcinoma (PTMC) is defined as a
papillary thyroid carcinoma equal to or less than 1 cm in
size, including extrathyroid extensions and/or nodal
metastases. Recent reports have suggested that the increas-
ing incidence of thyroid cancer is predominantly because
of the increased detection of small papillary cancers[1,2].
Most PTMCs are incidentally detected by histological
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analysis of thyroid glands removed for preoperatively
diagnosed benign diseases, or are indirectly diagnosed
because of the presence of enlarged metastatic cervical
lymph nodes or distant metastases [3,4]. In Korea and
Japan, however, where ultrasonography is frequently used
in the initial examination of thyroid glands [5-7], the inci-
dence of PTMC has increased explosively [8].
Although PTMC used to be considered a rather benign
entity with a very long indolent course, recent findings
indicate that PTMCs are frequently detected in patients
displaying factors associated with poor prognosis, includ-
ing multifocality, bilaterality, extrathyroid extension, and
lymph node metastasis [3,4,9-15]. The factors independ-
ently predictive of clinical recurrence in patients with
PTMC, however, have not been clearly determined [3,4,9-
15]. Thus, optimal management of PTMC patients can
range from observation without surgery at one extreme to
total thyroidectomy with therapeutic neck dissection fol-
lowed by radioiodine treatment at the other extreme,
depending on the presence of aggressive characteristics
[16]. To more clearly determine optimal management reg-
imens for PTMC patients, it is important to determine fac-
tors prognostic for clinical recurrence. We therefore
assessed prognostic parameters in 307 patients with
PTMC.
Methods
Definitions
PTMC was defined as "incidentally detected" when found
during the histological analysis of thyroid glands removed
for preoperatively diagnosed benign disease, when
detected by imaging methods during screening for other
purposes, or when found in the course of screening for
thyroid disease [16]. PTMC was defined as "occult" when
it was undetectable at clinical examination and was indi-
rectly diagnosed because of the presence of enlarged met-
astatic cervical lymph nodes or distant metastases [16].
Patients
Between January 1996 and December 2002, 1,262
patients with papillary thyroid carcinoma underwent ini-
tial thyroid surgery performed by one surgeon (S.J.H.) at
the Asan Medical Center, Seoul, Korea. Of these, 307
(24%) patients (32 men and 275 women), of mean age 46
± 10 years (range, 23 to 70 yrs), had tumors ≤ 1.0 cm in
diameter, including 292 patients with tumors of conven-
tional type, 14 with follicular variants, and 1 with an
oncocytic variant. The prevalence of PTMC increased over
time, with the proportion of PTMCs amongst all papillary
thyroid carcinomas being 17% (105 of 604 patients) in
1996–1999, 23% (106 of 416 patients) in 2000–2001,
and 40% (96 of 242 patients) in 2002.
Of the 307 patients with PTMCs, 20 had occult PTMCs,
with 19 diagnosed because of the presence of palpable
metastatic cervical lymph nodes and 1 diagnosed when a
distant lung metastasis was found. The remaining 287
patients had incidentally detected PTMCs; 271 PTMCs
were detected during imaging for other purposes in
screening for thyroid disease, and 16 were found during
pathological examination of thyroid specimens obtained
in the course of surgical resection for other conditions. Of
these, 10 patients underwent procedures for cosmetic
removal of large nodules, 4 were operated upon to
remove toxic multinodular goiters, and 2 patients under-
went surgery for Graves' disease.
Medical records of all subjects were retrospectively
reviewed, and patient demographics (age and gender),
histopathological findings (tumor size, multifocality,
bilaterality, extrathyroid extension, and cervical lymph
node metastasis), and clinical outcomes were analyzed.
Central cervical lymph nodes were defined as lymph
nodes at level VI (i.e., pretracheal, paratracheal, and prela-
ryngeal/Delphian lymph nodes), and patients with metas-
tases in these lymph nodes were classified as N1a
according to the 2002 TNM staging. Lateral cervical lymph
nodes were defined to include all unilateral cervical
lymph nodes except for those at level VI, as well as bilat-
eral, contralateral cervical, and superior mediastinal
lymph nodes; patients with metastases in these lymph
nodes were classified as N1b according to the 2002 TNM
staging.
Informed consent was obtained from all subjects at the
time of surgery, and our institutional ethics committee
approved this retrospective review protocol.
Initial treatment
Hemi- or subtotal thyroidectomy was initially performed
on 141 patients. These included 112 cases with preopera-
tive cytological diagnoses of PTMC but with no evidence
of extrathyroid extensions or lymph node metastases, and
clear contralateral lobes on preoperative thyroid ultra-
sonography. A further 21 patients showed indeterminate
preoperative cytology, including follicular neoplasms and
suspicion of PTC (papillary thyroid carcinoma). The final
8 patients with PTMC were diagnosed when their thyroids
were removed for preoperatively diagnosed benign dis-
eases. Seven patients underwent further completion thy-
roidectomy. Thus, 134 (44%) patients underwent hemi-
or subtotal thyroidectomy. Central neck node dissection
was performed on 107 patients and lymph node metas-
tases to the central neck node(s) were pathologically con-
firmed in 47 (stage N1a).
Total or near-total thyroidectomy was performed on 173
patients (56%), including 7 with completion thyroidec-BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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tomy. Seventeen patients did not undergo neck dissection;
these patients either chose total thyroidectomy following
an inconclusive preoperative diagnosis to avoid a possible
second surgery after unilateral operation, or they had dis-
ease conditions requiring total thyroidectomy because of
bilateral underlying benign pathology. Routine central
neck node dissection without modified radical neck dis-
section was performed on 129 patients, regardless of
nodal metastasis observed during surgery. Central neck
node dissection with modified radical neck dissection was
performed on 27 patients; 20 with occult PTMC detected
by cytologically confirmed enlarged cervical lymph nodes
and 7 with suspected but not cytologically confirmed lat-
eral neck nodes detected by ultrasonography. Central neck
node metastasis with or without lateral neck node metas-
tasis was confirmed in 24 pN1b and 68 pN1a patients.
For pathologic examination, the whole thyroid gland was
cut into 5 mm slices, fixed, and examined to define the
dimensions of malignant lesions and to note multifocal-
ity. Pathology slides were reviewed by one experienced
pathologist (G.G).
Of the 173 patients who underwent total or near-total thy-
roidectomy, 163 were treated post-surgically with radioio-
dine (2.78–5.55 GBq), whereas 10 were not treated in this
manner. Of the latter patients, none had an extrathyroid
extension or lymph node metastasis by postoperative
pathology and all were younger than 45 years. All patients
received suppressive doses of L-T4. No patient received
external beam radiation treatment (EBRT) as initial ther-
apy.
Subsequent follow-up and localization of persistent or 
recurrent lesions
Post-surgical physical examinations were performed every
3–6 months. The 163 patients who received radioiodine
remnant ablation treatment underwent diagnostic WBS
(whole body scan) with 148 MBq [I131], and measure-
ments of serum thyroglobulin (Tg) levels during thyroid
hormone withdrawal (THW) were made every 1–2 years.
Patients with serum Tg>2 μg/liter during THW who were
negative for thyroglobulin antibody (TgAb), patients pos-
itive for serum TgAb, and patients with clinical suspicion
of recurrence, were examined using one or more non-radi-
oiodine imaging methods, including neck ultrasonogra-
phy, [F18]-deoxyglucose positron emission tomography
(FDG-PET), and/or chest computed tomography, to local-
ize normal and/or malignant thyroid tissues.
The remaining 144 patients (i.e., the 10 patients who
underwent total or near-total thyroidectomy without rem-
nant ablation and the 134 patients who underwent hemi-
or subtotal thyroidectomy) received neck ultrasonogra-
phy and serum thyroid-stimulating hormone (TSH)
measurements annually. The FDG-PET, chest CT, and
other imaging methods were employed when indicated.
Definition of clinical outcome
"Recurrence" was defined as persistence and/or reappear-
ance of disease after initial operation, as determined cyto-
logically or histopathologically. "Regional recurrence"
was defined as recurrence in nodes or the operative bed,
and "local recurrence" was defined as recurrence in the
remaining thyroid after initial hemi- or subtotal thyroid-
ectomy. The time to recurrence was defined as duration
between the date of first operation and date of detection
of recurrence by diagnostic procedure (for those who
recur) or last show-up date to our hospital (for those who
do not recur).
Statistical analysis
Categorical variables are presented as numbers and per-
centages, and were compared using chi-square or Fisher's
exact test. Continuous variables are presented as mean ±
SD and range.
The Kaplan-Meier method including the log rank test was
used to compare recurrence. Univariate analyses were per-
formed separately for each of the variables using Cox-
regression. Variables for which the P value was < .2 in uni-
variate analysis were included in a multivariate Cox-
regression model. A backward elimination process was
used to develop the final multivariate model, and
adjusted hazard ratio (HR) and 95% confidence intervals
(CI) were calculated. P value of < .05 were considered sig-
nificant. All statistical analyses were performed using SAS
release 9.1.
Results
Clinical parameters
The mean tumor size was 0.8 ± 0.2 cm (range, 0.1–1.0
cm). Of the 307 patients, 84% had tumors > 0.5 cm in
size, 32% had multifocal tumors, 19% had bilateral
tumors, 38% had extrathyroid extensions of tumors, 37%
had central neck node metastases (pN1a), and 9% had lat-
eral neck node metastases (pN1b). Distant metastasis at
the time of presentation was observed in only one patient.
Of the 174 patients with extrathyroid extensions, only one
showed gross invasion involving adjacent neck structures
(pT4a), whereas 173 showed microscopic minimal
extrathyroid extensions (pT3).
Comparison of baseline clinical characteristics according 
to surgical extent (Table 1)
Age at diagnosis and the rates of multifocality, extrathy-
roid extension, and lymph node metastasis differed signif-
icantly between patients who underwent total or near-
total thyroidectomy and those who underwent hemi- or
sub-total thyroidectomy (Table 1).BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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Comparison of baseline clinical characteristics according 
to multifocality (Table 1)
When we assessed baseline characteristics relative to post-
surgically determined multifocality, we found that tumor
size was significantly larger in patients with multifocal
tumors than in those with solitary tumors, as was the fre-
quency of extrathyroid extension and lymph node metas-
tasis, especially in the lateral neck nodes. In addition,
patients with multifocal tumors more frequently under-
went total or near-total thyroidectomy than did those
with solitary tumors (Table 1).
Clinical characteristics of patients with recurrence
Clinical recurrence was evaluated in 306 patients who ini-
tially presented with PTMCs but without distant metas-
tases; of these, 293 patients were eligible for analysis, with
a median follow-up time of 65 months (range 5–139
months). These included 166 of the 172 patients who
underwent total or near-total thyroidectomy and 127 of
the 134 who underwent hemi- or subtotal thyroidectomy.
Of these 293 patients, 14 (5%) had clinical recurrences
during follow-up (Table 2). Regional recurrence in nodes
or the thyroid bed was observed in 9 patients (patients 1–
9 in Table 2), and local recurrence in the thyroid was
observed in 5 patients (patients 10–14 in Table 2). Of the
8 patients who underwent total or near-total thyroidec-
tomy and had recurrences (patients 1 to 8 in Table 2), 7
had regional recurrences in cervical lymph nodes and 1 in
the thyroid bed. Two of these patients showed newly
developed pulmonary metastases (patients 5 and 7 in
Table 2), which were detected by increases in serum Tg
levels and FDG uptake on scanning, and the appearance
of visible nodules on chest CT scans. These two patients,
initially staged as pT1N1b and pT3N1b, respectively,
underwent additional surgery followed by radioiodine
treatment, but no iodide uptake was detected during post-
treatment whole body scans. One patient (patient 5 in
table 2) showed progressive multiple unresectable cervi-
cal, mediastinal, and lung metastases, and EBRT was per-
formed to control locally advanced disease. The other case
(patient 7 in Table 2) was treated by thyroxine suppres-
sion, and definitive evidence of disease progression was
not observed by serial chest CT scan.
Of the 6 patients who underwent hemi- or subtotal thy-
roidectomy (patients 9 to 14 in Table 2), 1 suffered a
Table 1: Baseline clinical characteristics relative to surgical extent and tumor multifocality
Baseline 
characteristics
Surgical extent Tumor multifocality Overall
Total or near-total 
(n = 173)
Hemi- or subtotal 
(n = 134)
P valuea Multifocal (n = 98) Solitary (n = 209) P valuea
Age at operation 
(> 45 yrs)
95 (55) 54 (40) 0.01 53 (54) 96 (46) 0.22 149 (49)
Gender (male) 16 (9) 16 (12) 0.46 9 (9) 23 (11) 0.69 32 (10)
Tumor size
≤ 0.5 cm 29 (17) 20 (15) 0.07 9 (9) 40 (19) 0.04 49 (16)
> 0.5 cm and 
≤ 0.8 cm
63 (36) 66 (49) 40 (41) 89 (43) 129 (42)
> 0.8 cm 81 (47) 48 (36) 49 (50) 80 (38) 129 (42)
Multifocal tumor 84 (49) 14 (10) < .001 N/A N/A N/A 98 (32)
Bilateral tumor 57 (33) N/A 57 (69) N/A N/A 57 (19)
Extrathyroid 
extension
77 (45) 39 (29) 0.006 47 (48) 69 (33) 0.02 116 (38)
Lymph node 
metastasis
pNx 17 (10) 27 (20) < 0.001 13 (13) 31 (15) 0.03 44 (14)
pN0 64 (37) 60 (45) 30 (31) 94 (45) 124 (40)
pN1ab 68 (39) 47 (35) 43 (44) 72 (34) 115 (37)
pN1bc 24 (14) 0 12 (12) 12 (6) 24 (8)
Remnant 
ablation
163 (94) N/A 81 (83) 82 (39) < .001 163 (53)
Total or near-
total 
thyroidectomy
N/A N/A 84 (86) 89 (43) < .001 173 (56)
a by Fisher's exact test except for tumor size and lymph node metastasis; by the chi-squared test for tumor size and lymph node metastasis.
b Metastasis to level VI lymph nodes (pretracheal, paratracheal, and prelaryngeal/Delphian), classified as N1a in the 2002 TNM staging.
c Metastasis to unilateral, bilateral, or contralateral cervical superior mediastinal lymph nodes, classified as N1b in the 2002 TNM staging.
Percentages are given in parentheses; N/A, not applicable.BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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Table 2: Clinical characteristics of patients with clinical recurrence
Patient No. 1 2 3 4 5 6 7
Age/Sex 46/M 32/M 43/M 38/F 60/F 44/F 63/F
Initial Surgical 
extent
TT, MRND TT, CND TT, MRND TT, MRND TT, MRND TT, CND TT, MRND
I-131 Remnant 
ablation
done Done done done Done done done
Just before 
recurrence
sTg (ng/mL) 58.6 34.4 17.3 13.8 33 21.5 20.7
TgAb negative Negative negative positive negative negative negative
Disease free 
survival 
(months)
91 1 1 3 2 4 3 1 3 5 4 3
Type of 
recurrence 
(Level of 
recurrent node 
confirmed by 
reoperation)c
regional 
(i/l II, III, IV)
regional 
(i/l III, SCN)
regional 
(i/l II, III, IV)
regional 
(i/l II, III, IV, SCN, VII)
regional (thyroid bed) regional 
(i/l IV; c/l III, IV)
regional 
(i/l II, III, IV)
Additional 
treatment
surgery, 131I surgery, 131I surgery, 131I, EBRT surgery surgery, 131I, EBRT surgery, 131Is u r g e r y ,   131I
Follow-up
sTg (ng/mL) UD 12.6 1.1 8.7 944a 12.4 40.0b
TgAb negative negative negative positive negative negative negative
Patient No. 8 9 10 11 12 13 14
Age/Sex 42/F 50/F 40/F 43/F 32/F 40 M 33/M
Initial Surgical 
extent
TT, MRND STT LOB LOB LOB, CND LOB, CND LOB, CND
I-131 Remnant 
ablation
done not done not done not done not done not done not done
Just before 
recurrence
sTg (ng/mL) 1.1 N/A N/A N/A N/A N/A N/A
TgAb neg N/A N/A N/A N/A N/A N/A
Disease free 
survival 
(months)
99 8 10 15 44 53 63
Type of 
recurrence 
(Level of 
recurrent node 
confirmed by 
reoperation)c
regional 
(i/l II, III)
regional 
(i/l III, IV)
local (c/l lobe) local (c/l lobe) local (c/l lobe) local (c/l lobe) local (c/l lobe)
Additional 
treatment
surgery, 131I surgery, 131I follow-up loss surgery, 131I surgery, 131I surgery, 131Is u r g e r y ,   131I
Follow-up
sTg (ng/mL) UD UD UD UD UD UD
TgAb negative positive negative negative negative negative
a Chest CT suggested multiple lung metastases. This patient underwent additional surgery and radioiodine treatment, but no iodide uptake was noted 
during a post-treatment whole body scan. This patient, however, showed progressive, multiple, unresectable, cervical, mediastinal, and lung 
metastases, and EBRT was performed to control locally advanced disease.
b Chest CT and FDG-PET suggested multiple lung metastases. This patient underwent additional surgery and radioiodine treatment, but no iodide 
uptake was noted during a post-treatment whole body scan. This was followed by thyroxine suppression, with no definitive evidence of disease 
progression observed on serial chest CT scans.
sTg, stimulated thyroglobulin; TT, total thyroidectomy; STT, subtotal thyroidectomy; LOB, lobectomy; CND, central neck node dissection; MRND, 
modified radical neck dissection; UD, undetectable; N/A, not applicable; i/l, ipsilateral; c/l, contralateral; EBRT, external beam radiation treatment.BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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regional recurrence (patient 9) and 5 had local recurrences
in the contralateral lobe of the remaining thyroid
(patients 10–14 in Table 2). Five patients (patients 9 and
11 to 14 in Table 2), who were treated by re-operation fol-
lowed by radioiodine therapy, achieved complete nega-
tive conversion of stimulated serum Tg level.
Univariate analyses of factors predicting clinical 
recurrence according to surgical extent (Table 3)
Univariate analysis showed that, in patients who under-
went total or near-total thyroidectomy, presence of cervi-
cal lymph node metastasis at initial surgery (p = 0.01, Fig.
1A) and gender (p = 0.02, Fig 1B) were significantly asso-
ciated with clinical recurrence. In patients who underwent
partial thyroidectomy, however, there were no significant
associations between clinicopathological parameters and
clinical recurrence. The Kaplan-Meier estimate curves for
cervical lymph node metastasis and gender are shown in
Fig. 2A and Fig. 2B, respectively. Amongst the overall
patient cohort, regardless of surgical extent, the presence
of cervical neck lymph node metastases at initial surgery
(p = 0.049) and gender (p = 0.003) were significantly
associated with tumor recurrence.
Subgroup analyses of factors predicting clinical recurrence 
according to surgical extent after excluding patients with 
pNx staging (Table 4)
Subgroup analysis was also performed on the 251 PTMC
patients on whom information on pathologic N staging
was available, after excluding the 42 patients with pNx
Table 3: Univariate analyses of clinical recurrence with clinicopathological parameters in 293 patients with PTMC, according to 
surgical extent
Baseline 
characteristics
Patients with total or near-total thyroidectomy 
(n = 166)
Patients with hemi- or subtotal thyroidectomy 
(n = 127)
Overall (n = 293)
HR 95% CI P HR 95% CI Pa HR 95% CI P
Age at 
operation
≤ 45 yrs 1.88 0.45–7.90 0.39 3.19 0.37–27.3 0.29 2.28 0.71–7.27 0.16
> 45 yrs 1.00 - - 1.00 - - 1.00 - -
Gender
Men 5.92 1.41–24.8 0.02 4.6 0.83–25.4 0.96 5.22 1.74–15.6 0.003
Women 1.00 - - 1.00 - - 1.00 - -
Tumor size
Per 1 mm 
increase
1.21 0.82–1.78 0.35 1.01 .0.68–1.51 0.96 1.11 0.85–1.45 0.45
Multifocality
Solitary 
tumor
1.48 0.35–6.19 0.59 0.25 0.05–1.36 0.11 0.87 0.29–2.59 0.8
Multifocal 
tumor
1.00 - - 1.00 - - 1.00 - -
Extrathyroid 
extension
Absent 0.5 0.12–2.09 0.34 0.37 0.08–1.86 0.23 0.45 0.16–1.31 0.14
Present 1.00 - - 1.00 - - 1.00 - -
Lymph node 
metastasis
0.08 0.83 0.049
pNx 0 NC 1 1.64 0.33–8.14 0.54 1.62 0.39–6.79 0.51
pN0 0 NC 1 0 NC 0.99 0 NC 0.99
pN1aa 1.00 - - 1.00 - - 1.00 - -
pN1bb 8.25 1.66–40.9 0.01 N/A 5.25 1.60–17.3 0.51
Bilaterality
Unilateral 
tumor
0.71 0.17–2.97 0.64 N/A 0.81 0.23–2.90 0.74
Bilateral 
tumor
1.00 - - 1.00 - -
Remnant 
ablation
Not done 0 NC 1 N/A N/A
Done 1.00 - -
a Metastases to level VI lymph nodes (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes), classified as N1a in the 2002 TNM staging.
b Metastases to unilateral, bilateral, or contralateral cervical superior mediastinal lymph nodes, classified as N1b in the 2002 TNM staging.
Percent recurrence rates were given in parentheses; HR, hazard ration; CI, confidence interval; N/A, not applicable; INF, infinite; NC, cannot 
calculateBMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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staging. Amongst patients who underwent total or near-
total thyroidectomy, gender (p = 0.02) and presence of
cervical lymph node metastasis at initial surgery (p = 0.04)
were significantly associated with clinical recurrence on
univariate analysis. Gender (p = 0.01) was also signifi-
cantly associated with clinical recurrence amongst
patients who underwent hemi- or subtotal thyroidec-
tomy. Amongst the overall patient cohort, regardless of
surgical extent, gender (p = 0.03) and the presence of neck
lymph node metastasis at initial surgery (p = 0.03) were
significantly associated with tumor recurrence.
Kaplan-Meier curves of disease-free survival according to (A)  lymph node metastasis and (B) gender in 166 patients with  papillary thyroid microcarcinoma who underwent total or  near-total thyroidectomy Figure 1
Kaplan-Meier curves of disease-free survival accord-
ing to (A) lymph node metastasis and (B) gender in 
166 patients with papillary thyroid microcarcinoma 
who underwent total or near-total thyroidectomy. 
The curves for pN0 and pNx overlapped because no recur-
rence was observed in either group.
Kaplan-Meier curves of disease-free survival according to (A)  lymph node metastasis and (B) gender in 127 patients with  papillary thyroid microcarcinoma who underwent hemi- or  subtotal thyroidectomy Figure 2
Kaplan-Meier curves of disease-free survival accord-
ing to (A) lymph node metastasis and (B) gender in 
127 patients with papillary thyroid microcarcinoma 
who underwent hemi- or subtotal thyroidectomy.BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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Multivariate Analyses of predicting factors for clinical 
recurrence according to surgical extent (Table 5 and 6)
Multivariate analysis, both for all 293 eligible PTMC
patients (table 5) and for the 251 patients remaining after
exclusion of those with pNx staging (table 6), showed that
cervical node metastasis and gender were independently
associated with clinical recurrence
Discussion
Most PTMCs are incidentally detected during the histolog-
ical analysis of thyroid glands removed for preoperatively
diagnosed benign disease, or are indirectly diagnosed
because of the presence of enlarged metastatic cervical
lymph nodes or distant metastases [3,4]. A smaller pro-
portion of these tumors is detected during imaging of the
neck for other purposes, such as parathyroid evaluation,
using (for example) carotid Doppler, CT, and FDG-PET.
In Korea and Japan, however, many health care centers
perform ultrasonography during initial examination of
the thyroid [5-7], and impalpable nodules have increas-
ingly been discovered. Korea is a country without iodine
deficiency [17] and many thyroids have only one nodule,
making ultrasound an excellent method to detect PTMCs.
Furthermore, the incidence of PTMC diagnosed by ultra-
sonography screening for thyroid disease, and by fine nee-
dle aspiration cytology (FNAC) guided by
ultrasonography, has increased dramatically, as has the
proportion of PTMC procedures amongst all thyroid can-
Table 4: Subgroup analyses of association of clinical recurrence in 251 patients with PTMC according to surgical extent after excluding 
patients without pathologic N staging information
Baseline 
characteristics
Patients with total or near-total thyroidectomy 
(n = 150)
Patients with hemi- or subtotal thyroidectomy 
(n = 101)
Overall (n = 251)
HR 95% CI P HR 95% CI P HR 95% CI P
Age at 
operation
≤ 45 yrs 1.75 0.41–7.39 0.45 INF NC 0.99 2.38 0.63–8.98 0.20
> 45 yrs 1.00 - - 1.00 - - 1.00 - -
Gender
Men 5.35 1.28–22.4 0.02 24.2 2.17–270 0.01 7.59 2.31–25.0 0.001
Women 1.00 - - 1.00 - - 1.00 - -
Tumor size
Per 1 mm 
increase
1.17 0.79–1.72 0.44 1.36 .0.67–2.76 0.4 1.23 0.86–1.74 0.26
Multifocality
Solitary 
tumor
1.58 0.38–6.62 0.53 0.18 0.02–1.93 0.16 0.9 0.26–3.08 0.86
Multifocal 
tumor
1.00 - - 1.00 - - 1.00 - -
Extrathyroid 
extension
Absent 0.53 0.13–2.23 0.39 INF NC 1 0.77 0.23–2.52 0.66
Present 1.00 - - 1.00 - - 1.00 - -
Lymph node 
metastasis
0.04 1 0.03
pN0 0 NC 1 0 NC 0.99 0 NC 0.99
pN1aa 1.00 - - 1.00 - - 1.00 - -
pN1bb 8.25 1.66–40.9 0.01 N/A 5.14 1.56–17.0 0.007
Bilaterality
Unilateral 
tumor
0.74 0.18–3.11 0.69 N/A 0.65 0.17–2.47 0.53
Bilateral 
tumor
1.00 - - 1.00 - -
Remnant 
ablation
Not done 0 NC 1 N/A N/A
Done 1.00 - -
a Metastases to level VI lymph nodes (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes), classified as N1a in the 2002 TNM staging.
b Metastases to unilateral, bilateral, or contralateral cervical superior mediastinal lymph nodes, classified as N1b in the 2002 TNM staging.
Percent recurrence rates were given in parentheses; CI, confidence interval; N/A, not applicable; INF, infinite; NC, cannot calculate; HR, hazard 
ratio.BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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cer surgeries, to attain a level of about 50% in Korea [8].
We found that the proportion of PTMCs amongst all pap-
illary thyroid carcinomas increased over time, from 16%
to 40% between 1996 and 2002, a finding in agreement
with previous reports [1,2,18]. Only 5% of PTMCs were
incidentally detected during pathological examinations of
thyroid specimens resected for other diseases; this figure is
lower than the 21% to 67% previously reported
[3,4,10,15]. This may be because of the increased inci-
dence of PTMC diagnosed by screening ultrasonography
and FNAC in Korea.
We found that recurrence in some patients was detected
after a very short follow-up period. These patients were
evaluated before and after surgery by ultrasonography,
probably the most useful method for discovery of PTMC
node metastases, with a positive predictive value greater
than 80% [19]. However, the sensitivity and negative pre-
dictive value of ultrasonography for diagnosis of node
metastasis were 38% and 66%, respectively [12]. Further-
more, PTMC patients without evidence of positive lymph
nodes by ultrasonography did not undergo neck dissec-
tion, so their exact nodal staging remains unclear. Ultra-
sonography has been reported to be relatively insensitive
(~50%) for discovery of small PTMC foci in the contralat-
eral lobe [12], suggesting that many false-negative find-
ings may be made even when ultrasonography is
performed by skilled operators. Thus, the relatively short
period to recurrence after initial surgery may be because of
limitations caused by the relatively low sensitivity of pre-
operative ultrasonographic evaluation. Nevertheless, this
method should be regarded as the single most important
tool to determine the extent of surgery.
Cervical lymph node metastasis has been reported to
occur in 12–64% of PTMC patients [3,4,9-15] and may be
Table 5: Multivariate analyses of clinical recurrence with clinicopathological parameters in 293 patients with PTMC according to 
surgical extent
Baseline 
characteristics
Patients with total or near-total thyroidectomy 
(n = 166)
Patients with hemi- or subtotal thyroidectomy 
(n = 127)
Overall (n = 293)
HR 95% CI P HR 95% CI P HR 95% CI P
Gender
Men 4.58 1.08–19.5 0.04 4.6 0.83–25.4 0.08 4.9 1.62–14.8 0.005
Women 1.00 - - 1.00 - - 1.00 - -
Lymph node 
metastasis
0.12 0.049
pNx 0 NC 0.99 1.85 0.44–7.79 0.4
pN0 0 NC 1 0 NC 0.99
pN1aa 1.00 - - 1.00 - -
pN1bb 7.32 1.46–36.7 0.015 4.91 1.49–16.2 0.009
a Metastases to level VI lymph nodes (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes), classified as N1a in the 2002 TNM staging.
b Metastases to unilateral, bilateral, or contralateral cervical superior mediastinal lymph nodes, classified as N1b in the 2002 TNM staging.
HR, hazard ratio; CI, confidence interval; NC, cannot calculate
Table 6: Multivariate subgroup analyses of association of clinical recurrence in 251 patients with PTMC according to surgical extent 
after excluding patients without pathologic N staging information
Baseline 
characteristics
Patients with total or near-total thyroidectomy 
(n = 150)
Patients with hemi- or subtotal thyroidectomy 
(n = 101)
Overall (n = 251)
HR 95% CI P HR 95% CI P HR 95% CI P
Gender
Men 4.58 1.08–19.5 0.04 24.2 2.17–270 0.01 6.51 1.97–21.5 0.002
Women 1.00 - - 1.00 - - 1.00 - -
Lymph node 
metastasis
0.053 0.04
pN0 0 NC 0.99 0 NC 0.99
pN1aa 1.00 - - 1.00 - -
pN1bb 7.32 1.46–36.7 0.015 4.71 1.42–15.6 0.01
a Metastases to level VI lymph nodes (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes), classified as N1a in the 2002 TNM staging.
b Metastases to unilateral, bilateral, or contralateral cervical superior mediastinal lymph nodes, classified as N1b in the 2002 TNM staging.
HR, hazard ratio; CI, confidence interval; NC, cannot calculateBMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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a PTMC prognostic factor [9-15]. Recently, however, path-
ologically confirmed lateral neck metastasis, not central
neck node metastasis, was reported to be a strong predic-
tor of relapse in PTMC patients [12,13]. Our multivariate
analysis also found that lateral cervical node metastasis
was the most powerful independent predictor of clinical
recurrence, after adjusting for other variables.
Although we found that the male gender was significantly
associated with a higher clinical recurrence rate, the asso-
ciation was lost after adjusting for other variables. In con-
trast, no previous studies have reported an association of
gender with clinical recurrence in PTMC patients [3,4,9-
15], suggesting that additional studies are needed to con-
firm this association.
We also found that microscopic extrathyroid extension
was not associated with poor prognosis in PTMC patients,
a finding in agreement with previous results [3,4,10-15].
Further studies are needed to clarify whether the presence
of a pT3 lesion is an independent risk factor for poor prog-
nosis. Previous studies have reported that 42–79% of
PTMC patients had tumors ≥ 0.5 cm in size [3,4,9-
11,14,15], and 15–40% had multifocal tumors [3,4,9-
11,14,15]. Tumor recurrence may be associated with
tumor size [4] and multifocality [11,15]. We also
observed an association between multifocality and tumor
size, as well as with greater extrathyroid extension and
more extensive cervical nodal recurrence. In comparison
with previous studies, which reported that 70–81% of
patients with recurrence had multifocal tumors at initial
presentation, we found that only 36% of clinical recur-
rences were associated with multifocal disease in this
study, and that this multifocality was not significantly
associated with clinical recurrence. We cannot explain this
discrepancy, but initial total or near-total thyroidectomy
followed by the use of radioactive iodine ablation in our
patients may have obviated tumor recurrence in some
patients with multifocal disease.
Although previous studies reported that surgical extent
may influence clinical outcome [3,14], we found that
recurrence rates were similar in patients who underwent
hemi- or subtotal thyroidectomy to those in patients
receiving total or near-total thyroidectomy. However, the
clinical significance of these recurrences differed. All 8
patients with regional recurrences after total or near-total
thyroidectomy were re-treated by additional surgery, radi-
oiodine ablation, and/or EBRT; of these, 2 achieved com-
plete negative conversion of stimulated serum Tg and two
others showed progressive multiple lung metastases with
increasing Tg level. Most of these patients had lateral cer-
vical node metastases at initial presentation and under-
went modified radical neck dissection and radioiodine
treatment, but even these aggressive initial treatments
were insufficient to control their remaining disease. These
findings suggest that some patients with PTMC have
advanced disease with a very aggressive course, despite the
small size of the primary tumor, and that these patients
should be treated very aggressively, irrespective of primary
tumor size.
In the hemi- or subtotal thyroidectomy group, 6 patients
had recurrences, most with local tumors in the contralat-
eral lobes without extrathyroid involvement. Five of these
patients, who were treated by re-operation and subse-
quent radioiodine ablation, achieved complete negative
conversion of stimulated serum Tg level, indicative of
complete remission. These patients may be regarded as
having multifocal tumors detected over time, which might
show different biological behaviors than the tumors char-
acteristic of persistent disease after initial total or near-
total thyroidectomy, with or without radioiodine treat-
ment. Thus, hemi- or subtotal thyroidectomy alone may
be sufficient for some PTMC patients without evidence of
cervical lymph node metastasis or extrathyroid extension,
and clear contralateral lobes, as confirmed by preopera-
tive ultrasonography.
Because PTMC is associated with an excellent prognosis
after surgical removal, large numbers of patients with
extremely long-term follow-up are needed to identify the
clinical relevance of factors prognostic for recurrence
[3,4,9-15]. In contrast, we recruited only a relatively small
number of eligible PTMC patients, and the median fol-
low-up period was short. The lack of association between
previously determined prognostic factors and clinical
recurrence in this study may have resulted from these lim-
itations in sample size and follow-up duration. Despite
these limitations, our findings suggest the need for larger
studies to assess the relationships between lateral neck
node metastasis and/or gender with clinical recurrence in
patients with PTMC.
The choice of surgical extent for patients with PTMC is
unclear, with previous reports showing that 17–91%
undergo total or near-total thyroidectomy [3,4,8,9,11-
15]. Our results suggest that hemi- or subtotal thyroidec-
tomy may be sufficient for patients with no evidence of
cervical lymph node metastasis or extrathyroid extension
and clear contralateral lobes. It has been suggested, how-
ever, that a significant proportion of patients with PTMC
without regional metastasis can be managed by observa-
tion alone or by suppression therapy with follow-up using
ultrasonography [20,21], but no long-term follow-up
studies are available to support this approach. Appropri-
ately extensive surgery, according to prognostic parame-
ters such as lateral cervical node metastasis and gender,
may therefore be the standard therapy for PTMC patients.BMC Cancer 2008, 8:296 http://www.biomedcentral.com/1471-2407/8/296
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Conclusion
PTMCs showed very diverse clinical manifestations, with
some having very aggressive clinical behavior, despite
small primary tumor size. Clinical recurrence was associ-
ated with lateral cervical lymph node metastasis and the
male gender, but not with the presence of microscopic
extrathyroid extension. Multifocal diseases should be
treated with total or near-total thyroidectomy followed by
radioactive iodine ablation. In some patients with lateral
cervical node involvement, very aggressive treatment is
mandatory; but in some patients with unilateral disease
limited to one lobe, unilateral thyroidectomy with atten-
tive follow-up may be sufficient. Selection of proper man-
agement strategies for individual patients should be based
on the results of longer-term follow-up studies with larger
numbers of patients.
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